IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INC (IONS) is a US-listed equity tracked across major market indices. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

The company reports trailing twelve-month revenue of $203.33M and net loss of $92.53M. Key metrics include a return on equity of -18.8%, a debt-to-equity ratio of 6.02.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for IONS to support both active traders and long-term investors.